Needham & Company LLC Reiterates Buy Rating for Celcuity (NASDAQ:CELC)

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $122.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 6.18% from the company’s previous close.

CELC has been the topic of a number of other reports. Jefferies Financial Group raised their price objective on Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 target price (up from $77.00) on shares of Celcuity in a research note on Monday, November 17th. Wolfe Research reiterated an “outperform” rating and set a $110.00 price target on shares of Celcuity in a research report on Thursday. Wells Fargo & Company initiated coverage on shares of Celcuity in a research note on Friday, December 12th. They set an “overweight” rating and a $126.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and a consensus price target of $108.63.

Celcuity Stock Performance

NASDAQ CELC opened at $114.90 on Tuesday. Celcuity has a 52-week low of $7.57 and a 52-week high of $120.32. The company has a fifty day moving average of $109.02 and a 200-day moving average of $87.77. The company has a market capitalization of $5.32 billion, a P/E ratio of -31.31 and a beta of 0.38. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26.

Insider Transactions at Celcuity

In other Celcuity news, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the transaction, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. The trade was a 18.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.78% of the stock is currently owned by insiders.

Institutional Trading of Celcuity

A number of institutional investors have recently made changes to their positions in CELC. Ogorek Anthony Joseph NY ADV purchased a new position in shares of Celcuity in the third quarter worth $27,000. EverSource Wealth Advisors LLC boosted its position in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the period. US Bancorp DE boosted its position in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the period. BNP Paribas Financial Markets grew its holdings in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in shares of Celcuity in the fourth quarter valued at about $42,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.